
    
      An open-label, multicenter, single-dose, single-period, sequential study with the primary
      objective of assessing the effect of moderate renal impairment on the PK of surufatinib
      following administration of 300mg single oral dose. The secondary objective is to evaluate
      the safety in subjects with moderate renal impairment and subjects with normal renal function
      following a single oral dose of 300mg surufatinib.

      Approximately 16 subjects will be enrolled
    
  